Morning Call: Tradi...
Health Care: Drugs
Arena Pharmaceuticals Inc. (ARNA: NASDAQ)
$7.98 0.00 | 0.00%
05/20/13 - 12:56 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 27.59M | 12.72M | 16.61M | 10.39M |
| Cost of Sales | 3.67M | 8.10M | 7.41M | 6.54M |
| Gross Operating Profit | 23.92M | 4.62M | 9.20M | 3.85M |
| Selling, General, and Administrative Expenses | 26.23M | 24.25M | 27.94M | 25.25M |
| Research & Development | 54.11M | 58.71M | 75.46M | 110.16M |
| Operating Income before D & A (EBITDA) | -56.42M | -78.34M | -94.20M | -131.56M |
| Depreciation & Amortization | 11.26M | 11.56M | 13.10M | 14.93M |
| Interest Income | 119.00K | 117.00K | 469.00K | 689.00K |
| Other Income - Net | -19.36M | -12.23M | -6.97M | 3.21M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -86.93M | -105.48M | -113.79M | -145.91M |
| Interest Expense | 9.12M | 14.31M | 21.68M | 18.72M |
| Pre-Tax Income | -96.05M | -119.79M | -135.47M | -164.63M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -85.48M | -109.22M | -124.53M | -153.20M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -85.48M | -109.22M | -124.53M | -153.20M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -85.48M | -109.22M | -124.53M | -153.20M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-85.48M | -105.76M | -124.53M | -149.88M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -85.48M | -109.22M | -124.53M | -153.20M |
| Basic EPS from Continuing Ops. | -0.45 | -0.80 | -1.14 | -1.82 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.45 | -0.80 | -1.14 | -1.82 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.45 | -0.80 | -1.14 | -1.82 |
| Basic Normalized Net Income/Share | -0.45 | -0.77 | -1.14 | -1.78 |
| EPS fr Continuing Ops. | -0.45 | -0.80 | -1.14 | -1.82 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.45 | -0.80 | -1.14 | -1.82 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.45 | -0.80 | -1.14 | -1.82 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.45 | -0.77 | -1.14 | -1.78 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ARNA
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Under-$10 Moving Hig...
- UserMy Watch List
- Usermichelle
- User2012 picks 10/28/20121
- Usermine
- ContributorStocks Under-$10 Moving Hig...
- UserMy SP portfolio
- UserMyfuture
- ContributorStocks Under-$10 Setting Up...
Latest ARNA Headlines from TheStreet
- Happy Day for Arena Bulls, Bears As Belviq Launch Finally Arrives 05.07.13 | 11:05 am
- Arena Stock Gaps Down On Today's Open (ARNA) 05.03.13 | 09:05 am
- Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy 04.12.13 | 06:04 am
- Large Vivus Shareholder Seeks More Change 04.10.13 | 10:04 am
- Arena Bulls, Bears Endure Annoyingly Long Wait for Belviq Launch 04.10.13 | 09:04 am
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- Vivus Piles New Debt On Top Of Excuses 03.26.13 | 10:03 am
- Arena Pharmaceuticals Inc. (ARNA): Health Care's Featured Stock Of The Day 03.25.13 | 05:03 pm
- 2 Drug Stocks Under $10 To Pick As Favorites 03.25.13 | 02:03 pm
- Best And Worst FDA Drug Approval Stocks of 2013 03.12.13 | 08:03 am
Press Releases for ARNA
- Pill Economics - Research Report On Arena Pharmaceuticals, Inc. And Amgen, Inc. - PR Newswire 01.23.13 | 08:01 am
- Stock Alerts For Coca-Cola, Deere, News Corp., Arena Pharmaceuticals, And American Tower Released By InvestorsObserver - PR Newswire 06.28.12 | 09:06 am
- Arena Pharmaceuticals Investigated By Goldfarb Branham Law Firm LLP - Business Wire 10.08.10 | 09:10 am
- Girard Gibbs LLP Files Class Action Lawsuit Against Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) - Business Wire 09.29.10 | 05:09 pm
- Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Against Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) - Business Wire 09.28.10 | 02:09 pm
- Investor Notice: The Rosen Law Firm Announces Filing Of Securities Class Action Against Arena Pharmaceuticals, Inc. - ARNA - Business Wire 09.22.10 | 06:09 pm
- Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Arena Pharmaceuticals, Inc. - Business Wire 09.22.10 | 05:09 pm
- The Law Office Of Robbins Umeda LLP Announces An Investigation Of Arena Pharmaceuticals, Inc. - Business Wire 09.22.10 | 12:09 pm
Partner Headlines for ARNA
- 4 Healthcare Stock Stories Prescribed for Investors - Wall St. Cheat Sheet 04.01.13 | 05:04 am
- 4 Healthcare Stock Stories Prescribed for Investors - Wall St. Cheat Sheet 04.01.13 | 05:04 am
- Fannie Mae And Freddie Mac, Short-Term Trade Or Deep Value Investment? - Seeking Alpha 03.25.13 | 09:03 am
- A Look At 3 Obesity Stocks - Seeking Alpha 03.05.13 | 09:03 am
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Pre-Market Earnings Report for March 4, 2013 : RIG, SSYS, TECD, ARNA, CEL, BYD, YGE, ALVR - NASDAQ 03.01.13 | 09:03 pm
- Arena's Recent Outperform Call And A Probability Weighted Valuation - Seeking Alpha 02.08.13 | 08:02 am
- Arena Must Wait For European Approval - Seeking Alpha 01.19.13 | 07:01 am
- Orexigen: The Best Bet In Obesity For 2013 - Seeking Alpha 12.17.12 | 09:12 am
- Arena Opening New Doors - Seeking Alpha 11.29.12 | 09:11 am
